Literature DB >> 20934169

Malignant peripheral nerve sheath tumor arising from benign vestibular schwannoma treated by gamma knife radiosurgery after two previous surgeries: a case report with surgical and pathological observations.

Yosuke Akamatsu1, Kensuke Murakami, Mika Watanabe, Hidefumi Jokura, Teiji Tominaga.   

Abstract

BACKGROUND: Gamma knife radiosurgery (GKRS) is an effective treatment for vestibular schwannomas with lower morbidity and mortality. However, malignant transformation associated with GKRS, although uncommon, has been reported in recent publications.
METHODS: We describe a case presenting with malignant peripheral nerve sheath tumor (MPNST) at 8 years after GKRS after incomplete resections.
RESULTS: The tumor appeared to be a typical benign schwannoma at the surgery preceding GKRS, and rapidly enlarged after long-term control, causing progressive neurological deterioration. Operative findings showed that the tumor was composed of two different components, and histopathology distinctively demonstrated MPNST and benign schwannoma.
CONCLUSIONS: The coexistence of benign and malignant components might indicate that the present MPNST had arisen from the benign schwannoma by transformation in association with GKRS.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20934169     DOI: 10.1016/j.wneu.2010.04.009

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  9 in total

Review 1.  Radiotherapy for prolactin-secreting pituitary tumors.

Authors:  Lawrence J Sheplan Olsen; Lizbeth Robles Irizarry; Samuel T Chao; Robert J Weil; Amir H Hamrahian; Betul Hatipoglu; John H Suh
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

2.  Malignant peripheral nerve sheath tumor at the cerebellopontine angle treated with Gamma Knife radiosurgery: case report and review of the literature.

Authors:  Daniel M S Raper; Fadi Sweiss; M Isabel Almira-Suarez; Gregory Helm; Jason P Sheehan
Journal:  J Radiosurg SBRT       Date:  2013

Review 3.  [Value of different strategies in the treatment of vestibular schwannoma: therapeutic aspects and literature analysis].

Authors:  W Maier; T D Grauvogel; R Laszig; G J Ridder
Journal:  HNO       Date:  2011-05       Impact factor: 1.284

Review 4.  Transition of a vestibular schwannoma to a malignant peripheral nerve sheath tumor with loss of H3K27 trimethylation after radiosurgery-a case report and review of the literature.

Authors:  Felix Behling; Imane Bersali; Antonio Santacroce; Johann Hempel; Kosmas Kandilaris; Jens Schittenhelm; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2021-08-15       Impact factor: 2.800

5.  Radiation-induced peripheral malignant nerve sheath tumor arising from vestibular schwannoma after linac-based stereotactic radiation therapy: a case report and review of literatures.

Authors:  Putipun Puataweepong; Taweesak Janwityanujit; Noppadol Larbcharoensub; Mantana Dhanachai
Journal:  Case Rep Med       Date:  2012-07-09

6.  Surgery After Surgery for Vestibular Schwannoma: A Case Series.

Authors:  Łukasz Przepiórka; Przemysław Kunert; Wiktoria Rutkowska; Tomasz Dziedzic; Andrzej Marchel
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244

7.  Outcomes of stereotactic radiosurgery in young adults with vestibular schwannomas.

Authors:  Mariko Kawashima; Hirotaka Hasegawa; Masahiro Shin; Yuki Shinya; Atsuto Katano; Nobuhito Saito
Journal:  J Neurooncol       Date:  2021-07-09       Impact factor: 4.130

8.  Updates on the diagnosis and treatment of intracranial nerve malignant peripheral nerve sheath tumors.

Authors:  Bénédicte L'heureux-Lebeau; Issam Saliba
Journal:  Onco Targets Ther       Date:  2013-04-26       Impact factor: 4.147

9.  Malignant Transformation in Vestibular Schwannoma: Clinical Study With Survival Analysis.

Authors:  Jiuhong Li; Qiguang Wang; Menglan Zhang; Guisheng Zhang; Si Zhang; Xuhui Hui
Journal:  Front Oncol       Date:  2021-04-14       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.